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A Magnificent Time With the “Magnificent Seven”
Transmembrane Spanning Receptors
Robert J. Lefkowitz
The largest, most ubiquitous, and most versatile of thereceptor gene families is that which encodes the seventransmembrane spanning receptors. In the cardiovas-
cular system, such receptors regulate, for example, the rate
and force of cardiac contraction, peripheral arterial resistance,
and various aspects of renal function. The larger superfamily
of receptors also regulates everything from sensory percep-
tion (vision, smell, taste) to hormonal and neurotransmitter
signaling, to immune functions such as chemotaxis. There is
virtually no area of human physiology in which they are not
implicated. A majority of prescription drugs sold target such
receptors either directly or indirectly. In the field of cardio-
vascular medicine, this is exemplified by - and -adrenergic
receptor agonists and antagonists, angiotensin receptor block-
ers, and angiotensin-converting enzyme inhibitors.
A profound alteration in our understanding of these recep-
tors occurred during the 1970s and 1980s, which transformed
everything from the way they are viewed, to how they are
studied, to how new drugs are discovered. I provide here a
very personal recollection and perspective of my own voyage
of discovery during this time, of its scientific antecedents, and
of the technical and conceptual barriers that needed to be
scaled.
The notion that biologically active substances initiate their
actions by binding with high affinity and selectivity to some
“receptive substance” on cells dates back about a hundred
years. Early work of Ehrlich on interactions of antigens with
cells and of chemotherapeutic agents with their targets was
made even more explicit by J.N. Langley and H.H. Dale who,
during the earliest years of the 20th century, studied actions
of cholinergic and adrenergic agonists and antagonists on
various target organs. Based on this early work, the period
from about 1920 to 1970 was characterized by the develop-
ment of classical theories of receptor action based on the law
of mass action. This work, carried out with intact physiolog-
ical preparations, was done by such giants of pharmacology
as Clark, Ariens, Stephenson, Black, and Furchgott.
The 1960s and 1970s witnessed the beginning of a merger
between receptor pharmacology and biochemistry, led by
individuals such as Earl Sutherland. His demonstration that a
proximate consequence of agonist activation of receptors,
such as those for adrenaline and glucagon, was stimulation of
the membrane-bound enzyme adenylate cyclase leading to
generation of the second messenger cAMP (cAMP), mark-
edly altered the landscape of receptor biology. Now, the
properties of the receptors could be inferred, not from some
very downstream physiological event but rather from a very
early biochemical readout, cAMP levels. This paradigm was
rapidly expanded to the receptors for numerous hormones and
neurotransmitters. With the discovery of protein kinase A
(PKA) as the immediate downstream effector of cAMP action
by Krebs, and of the guanine nucleotide binding proteins that
regulate the activity of adenylate cyclase by Rodbell and
Gilman, the outline of a concrete biochemical pathway of
receptor action had clearly emerged by the mid-1970s. But
the almost mythical receptors remained elusive and even
controversial.
Many classical pharmacologists of the time remained quite
skeptical that the receptors had any real physical reality. Their
attitude was typified by Raymond Ahlquist who, using
classical pharmacological techniques, in 1948 first proposed
the existence of separate - and -adrenergic receptors. As
late as 1973, he wrote: “This would be true if I were so
presumptuous as to believe that  and  receptors really did
exist. There are those that think so and even propose to
describe their intimate structure. To me they are an abstract
concept conceived to explain observed responses of tissues
produced by chemicals of various structure” (page 121).1
In contrast, biochemists like Sutherland were more com-
fortable with a molecular basis for drug and hormone action,
but still were not ready to accord to the receptors an
independent existence. Thus Sutherland wrote in 1967: “It
seems likely that in most and perhaps all tissues, the 
receptor and adenyl cyclase are the same. The results of many
previous studies have pointed to this conclusion, and we feel
that the studies with the perfused rat heart have added further
to its possible validity” (page 720).2
It was within this historical context that my own work on
the adrenergic receptors began in the early 1970s. It was
motivated by the relatively simple vision that receptors, such
as those that activate adenylate cyclase, were membrane
proteins, independent of their effectors, which might be
studied by appropriate adaptation of the techniques of protein
chemistry. The choice of the adrenergic receptors, and most
particularly of the 2-adrenergic receptor (2-AR) as my main
focus was based on several considerations. An overarching
interest in catecholamine action, however, was not one of
these. Rather, the choice was based on several practical
considerations. As a model system, I wanted a receptor that
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fulfilled several criteria. First, it should be widely distributed
in mammalian tissues, play important physiological roles, and
in view of my status at the time as a young academic
cardiologist, be relevant to cardiovascular biology. Second,
since I would clearly need to develop a variety of new
experimental approaches, availability of a large array of
ligands, both agonists and antagonists, which could be chem-
ically modified for my purposes, was paramount. At the time,
this latter requirement virtually eliminated all the receptors
for peptide and protein ligands. The adrenergic receptors,
however, appeared to fulfill all these criteria.
Ultimately, the success of our endeavor depended on
achieving a series of technical breakthroughs that allowed
ever closer access to the mysteries of the receptors. In
chronological order, these are listed below.
Radioligand Binding: In the early to mid 1970s, we
developed radioligands for the direct study, first, of the
-ARs, and then of the -ARs. Such approaches allowed the
properties of the receptors to be measured directly, rather than
being inferred from downstream biochemical or physiologi-
cal readouts. These methods permitted quantitation of the
receptors, elucidation of the factors regulating their expres-
sion, discovery of the unique actions of guanine nucleotides,
and precise investigation and even discovery of new receptor
subtypes. They also transformed the way new drug candidates
were screened and discovered.
Photoaffinity Labeling Techniques: These were devel-
oped to tag the receptors during purification efforts.
Solubilization and Purification: This was a truly daunting
challenge because the receptors required 100 000- to
200 000-fold purification from membrane preparations. For
comparison, consider the situation with two other contempo-
raneous objects of study, the nicotinic cholinergic receptor,
which was being purified from the electroplax of the electric
fish torpedo, and rhodopsin, which was obtained from bovine
retina. These proteins each constitute more than 90% of all
the protein in purified membrane preparations from the
tissues of origin, such that almost no purification was re-
quired. The key to our purification efforts was the develop-
ment of affinity chromatography matrices. These ultimately
allowed us to purify to homogeneity all of the 4 known
subtypes of adrenergic receptors, the 1, 2, 1, and 2. Each
purified receptor consisted of a single polypeptide that bound
ligands with theoretical specific activity for one binding site
per receptor, with all the appropriate specificity and ste-
reospecificity characteristics. Still, skepticism persisted as to
whether these isolated molecules truly comprised the recep-
tors. These lingering doubts, however, were finally put to rest
with the development of reconstitution systems.
Reconstitution Techniques: The isolated 2-adrenergic
receptors were initially transferred via liposomes to the
plasma membrane of cells, which lacked the receptors and
which accordingly lacked catecholamine-sensitive adenylate
cyclase (Xenopus laevus erythrocytes). Receptor fusion con-
veyed responsiveness to isoproterenol (a -adrenergic ago-
nist) on the previously unresponsive cells. Subsequently, we
reconstituted the receptors with various other purified com-
ponents of the system, culminating in the complete reconsti-
tution of the purified receptor, Gs, and adenylate cyclase into
a fully functional isoproterenol responsive system in 1984.
Receptor Cloning: With pure receptors in hand by the
early 1980s, our efforts turned to cloning. Despite never
having more than about 50 g of pure receptor at any one
time, small stretches of protein sequence were obtained from
cyanogen bromide fragments of the receptors, and these were
used to design oligonucleotide probes. The rarity of the
mRNAs for the receptors complicated initial cDNA cloning
attempts for more than a year. Eventually, the first clones for
the 2-AR were pulled from a genomic library. The fortuitous
absence of introns in the 2-adrenergic receptor gene greatly
facilitated the completion of its DNA sequence together with
our collaborators at Merck Pharmaceuticals.
Our discovery, published in May 1986, that the 2-AR
shared sequence homology and a predicted seven transmem-
brane spanning architecture with rhodopsin, came as a total
surprise to us and everyone else. In spite of the many
functional similarities between visual signaling and hormonal
activation of adenylate cyclase, it had not been anticipated
that the 2-AR and rhodopsin would share any structural
similarity. In fact, the complete amino acid sequence of
rhodopsin had been determined several years earlier by
conventional protein sequencing, since it was available in
such large amounts. However, its seven transmembrane
spanning arrangement was analogized only to the prokaryotic
light-sensitive protein pump bacteriorhodopsin and was not
yet conceived of as relevant to receptor biology.
Over the next several years, we cloned not only the original
four adrenergic receptor subtypes but an additional four not
previously clearly distinguished by pharmacological criteria,
as well as the first “orphan” G protein–coupled receptor,
which we subsequently identified as the serotonin 5HT1A
receptor. All of these receptors shared sequence similarity
and the seven transmembrane spanning organization, as did
the muscarinic cholinergic receptor cloned shortly thereafter
by Numa’s group. Thus, it rapidly became clear, as we had
originally speculated in the 1986 study on the cloning of the
2-AR, that a large family of G protein–coupled seven
transmembrane spanning receptors existed. This insight
greatly facilitated the cloning of the now huge superfamily of
such receptors since this could be done by homology
approaches.
Receptor Mutagenesis and Chimeric Receptors: Once
the cDNAs for the receptors were available, extensive mu-
tagenesis studies were rapidly accomplished in many labora-
tories. In addition, we utilized the approach of constructing
chimeric receptors between the adenylate cyclase stimulatory
2 and inhibitory 2 receptors. When a segment of the
2-receptor gene, including that portion which encodes the
third cytoplasmic loop, was transplanted into the 2-
adrenergic receptor gene, a hybrid receptor resulted which
bound ligands with the specificity of the 2 receptor, but
which activated adenylate cyclase through Gs, like the 2-
adrenergic receptor. These results helped shape current con-
cepts of seven transmembrane spanning receptor function in
which ligands are bound either by the membrane spanning
domains or external loops of the receptors, and G protein
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activation occurs through the cytoplasmic loops and carboxy
terminal tail.
In the course of our mutagenesis studies, we serendipi-
tously discovered the phenomenon of constitutively active
mutant receptors, ie, mutations that render the receptors
active even in the absence of agonist. This activity apparently
results from the abrogation of intramolecular interactions that
normally constrain the receptor to an inactive state. Such
mutations were subsequently found to occur spontaneously in
humans and to cause an ever growing list of illnesses.
A Universal Mechanism for Receptor Regulation: Con-
temporaneous with this work were efforts to uncover the
molecular basis for the virtually universal phenomenon of
desensitization of second messenger signaling, which occurs
during persistent stimulation of the receptors. By the early to
mid-1980s, we had concluded that the 2-adrenergic receptor
was phosphorylated in association with its desensitization.
Two kinases appeared to be active, PKA acting in a classical
feedback regulatory fashion, and a cAMP-independent ki-
nase. This latter we named the -adrenergic receptor kinase
or ARK, even in advance of its purification from bovine
brain.
A similar story had been evolving for regulation of visual
signaling by a molecule called rhodopsin kinase. When we
cloned ARK, now known as G protein–coupled receptor
kinase 2 (GRK2) and rhodopsin kinase (now known as
GRK1) and appreciated their sequence homology, we real-
ized that a gene family of such GRKs existed. Today, this
family has seven members (GRK1 to 7). Moreover, the GRKs
work in tandem with arrestins, molecules that bind to the
GRK-phosphorylated receptors to sterically interfere with
their coupling to the G proteins. Four arrestin genes exist in
mammals, two of which are limited in expression to the retina
and two of which are ubiquitously expressed (-arrestins 1
and 2, also known as arrestin 2 and 3). These molecules were
discovered because in 1987, we were trying to understand
why progressive purification of ARK led to loss of its
ability to desensitize the 2-AR in a reconstituted system.
When we added back the recently discovered visual arrestin
molecule, it restored desensitization, albeit at very high
concentrations. Postulating that an analogous molecule must
exist in nonvisual tissues, we ultimately cloned -arrestins 1
and 2 based on their homology with visual arrestin (also
known as arrestin 1). Today it is appreciated that this
2-component system of GRKs and arrestins universally reg-
ulates seven transmembrane spanning receptors. Moreover, in
addition to receptor desensitization, this system mediates
their clathrin-mediated internalization, and also links the
receptors to a growing number of signaling pathways, such as
non–receptor tyrosine kinases and mitogen-activated protein
kinases. The -arrestins thus serve as multifunctional signal-
ing adaptor and scaffold proteins.
In retrospect, the 20-year period from the early 1970s to the
early 1990s produced a paradigm shift in the way membrane
receptors are viewed and studied. The receptors were trans-
formed from nebulous concepts into discrete molecular enti-
ties that could be probed and manipulated to great therapeutic
benefit. In the course of this transformation, I was privileged
to observe at close range the birth and remarkably rapid
growth of this field. I consider myself fortunate indeed,
together with my many dozens of devoted and talented
students and fellows, to have played a role in all this. We have
truly had a magnificent time with the magnificent seven
transmembrane spanning receptors.
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